Enveric Biosciences to Participate in the Microdose Psychedelic Capital Conference on May 26, 2022
NAPLES, FLA, May 24, 2022 /PRNewswire/ - Enveric Biosciences , Inc.(NASDAQ:ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Avani Kanubaddi, President and Chief Operating Officer of Enveric, will participate virtually in Microdose's Psychedelic Capital: May 2022 Conference to be held virtually on May 26, 2022.
- NAPLES, FLA, May 24, 2022 /PRNewswire/ - Enveric Biosciences , Inc.(NASDAQ:ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, today announced that Avani Kanubaddi, President and Chief Operating Officer of Enveric, will participate virtually in Microdose's Psychedelic Capital: May 2022 Conference to be held virtually on May 26, 2022.
- Mr. Kanubaddi will participate on a panel "The Spinoffs - Divide and Conquer" on Thursday, May 26th at 4:05 p.m.
- The panel will discuss the latest spinoffs among publicly traded companies to stay competitive, honor the shareholders and combat the markets.
- Enveric Biosciences , Inc. (NASDAQ: ENVB) is a neuroscience-focused pharmaceutical company developing next-generation, psychedelic-inspired mental health medicines.